ATOS missed EPS expectations by 19.25%
Aug 16, 2025, 10:34 AM
0.00%
What does ATOS do
Atossa Therapeutics, based in Seattle, focuses on developing oral (Z)-endoxifen for breast cancer treatment and prevention, having completed four Phase I and two Phase II clinical studies. The company went public on November 8, 2012, and employs 10 people.
Atossa Therapeutics (ATOS) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Atossa Therapeutics's actual EPS was -$0.07, missing the estimate of -$0.06 per share, resulting in a -19.25% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.